bis(4-amino-3-methylcyclohexyl)methane: amine curing agent for epoxy resin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 91555 |
| CHEMBL ID | 3189048 |
| SCHEMBL ID | 27331 |
| MeSH ID | M0086532 |
| Synonym |
|---|
| 3,3'-dimethyl-4,4'-diaminodicyclohexylmethane |
| 2,2'-dimethyl-4,4'-methylenebis(cyclohexylamine) |
| bis(4-amino-3-methylcyclohexyl)methane |
| einecs 229-962-1 |
| cyclohexanamine, 4,4'-methylenebis(2-methyl- |
| 4,4'-methylenebis(2-methylcyclohexanamine) |
| cyclohexanamine, 4,4'-methylenebis[2-methyl- |
| 6864-37-5 |
| FT-0654737 |
| M1422 |
| 4,4'-methylenebis(1-amino-2-methylcyclohexane) |
| 4,4'-methylenebis(2-methylcyclohexylamine) |
| 4,4'-diamino-3,3'-dimethyldicyclohexylmethane |
| 4-[(4-amino-3-methylcyclohexyl)methyl]-2-methylcyclohexan-1-amine |
| NCGC00248934-01 |
| dtxcid209670 |
| cas-6864-37-5 |
| tox21_201139 |
| dtxsid6029670 , |
| NCGC00258691-01 |
| 3k4h01e55x , |
| ec 229-962-1 |
| unii-3k4h01e55x |
| AKOS015894511 |
| SCHEMBL27331 |
| dimethyldicyane |
| 2,2'-dimethyl-4,4'methylenebis(cyclohexylamine) |
| CHEMBL3189048 |
| 4,4'-methylenebis(2-methylcyclohexyl-amine) |
| J-514032 |
| F0001-1790 |
| mfcd00075535 |
| 4,4'-methylenebis(2- methylcyclohexylamine) |
| CS-0071366 |
| 4,4'-4,4'-methylenebis(cyclohexyl-amine) mix. isomers |
| Q27257384 |
| 4,4-methylenebis(2-methylcyclohexylamine) |
| 3,3'-dimethyl-4,4'-diaminodicyclohexylmethane 100 microg/ml in acetonitrile |
| AS-76067 |
| 4,4'-methylenebis(2-methylcyclohexylamine), mixture of isomers |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Amine-curing agent for epoxy resin, bis(4-amino-3-methylcyclohexyl)methane, has been suspected of inducing toxic symptoms in man which resemble collagen disease such as scleroderma or polymyositis." | ( [Subacute toxicity of an amine-curing agent for epoxy resin]. Matsumoto, M; Nakayama, E; Nishizawa, H; Ohsawa, M; Ohshima, S; Okuda, H; Sasaki, N; Shibata, T, 1984) | 0.54 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " These changes in the choroid plexus were closely correlated with the dosage of the agent administered and the period of administration." | ( Pathomorphological changes in rat brain choroid plexus due to administration of the amine-curing agent, bis(4-amino-3-methylcyclohexyl)methane. Ishizuka, M; Nakayama, E; Ohshima, S; Sasaki, N; Shibata, T; Shimizu, Y; Suzuki, M, 1990) | 0.49 |
| " Animals of high dosage group showed suppression of body weight increase and loss of muscular strength of limbs in the administration period." | ( [Subacute toxicity of an amine-curing agent for epoxy resin]. Matsumoto, M; Nakayama, E; Nishizawa, H; Ohsawa, M; Ohshima, S; Okuda, H; Sasaki, N; Shibata, T, 1984) | 0.27 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 0.7583 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 19.8162 | 0.0002 | 21.2231 | 8,912.5098 | AID743063 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 69.7072 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 12.3959 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 32.1658 | 0.0002 | 29.3054 | 16,493.5996 | AID743080; AID743091 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 12.5032 | 0.0237 | 23.2282 | 63.5986 | AID743223 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 5.5370 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 65.9169 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 62.1266 | 0.0006 | 27.2152 | 1,122.0200 | AID743202; AID743219 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.36) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||